DiaMedica Therapeutics Crescita futura
Criteri Future verificati 0/6
Si prevede che gli utili di DiaMedica Therapeutics diminuiranno del 8.2% all'anno, mentre si prevede che il fatturato annuo crescerà del 74.6% all'anno. Si prevede che l'EPS crescerà del 2.4% all'anno.
Informazioni chiave
-8.2%
Tasso di crescita degli utili
2.43%
Tasso di crescita dell'EPS
| Biotechs crescita degli utili | 25.2% |
| Tasso di crescita dei ricavi | 74.6% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Low |
| Ultimo aggiornamento | 08 May 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Companies Like DiaMedica Therapeutics (NASDAQ:DMAC) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Preeclampsia Breakthrough Potential And Strong Cash Runway Will Support Future Value Creation
Catalysts About DiaMedica Therapeutics DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing DM199, a KLK1 protein therapy, for vascular conditions such as preeclampsia, fetal growth restriction and acute ischemic stroke. What are the underlying business or industry changes driving this perspective?
Preeclampsia And Stroke Programs Will Drive Long Term Potential For This Biotech
Catalysts About DiaMedica Therapeutics DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing DM199, a recombinant KLK1 therapy, for vascular conditions such as preeclampsia, fetal growth restriction and acute ischemic stroke. What are the underlying business or industry changes driving this perspective?Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold
DiaMedica Therapeutics (NASDAQ:DMAC) on Wednesday said the U.S. FDA had placed a clinical hold on its phase 2/3 trial evaluating its product candidate DM199 for the treatment of a type of stroke called acute ischemic stroke. The trial, called ReMEDy2, was put on hold as three serious cases of low blood pressure in stroke patients were reported after they received an injection of DM199. The company said it had paused patient enrollment, and believes the low blood pressure events were due to the use of a different intravenous bag in the ReMEDy2 trial from the one used in the prior ReMEDy1 trial. "...the company is confirming the differences in drug absorption in the IV bags used in the ReMEDy1 trial compared to the ReMEDy2 trial and plans to work with the FDA to modify the ReMEDy2 trial protocol to adjust the DM199 IV dosing to more closely match the dosing in the ReMEDy1 trial, taking into account these differences", DMAC said. DMAC said that no such low blood pressure issues were reported in the ReMEDy1 trial.We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...DiaMedica: Proven Stroke Drug In Asia, Headed To The U.S.
DMAC is a microcap biotech that has the first potential breakthrough stroke drug in 25 years, which addresses a $3.5 billion U.S. market. They initiated a phase 2/3 pivotal trial. Their drug, DM199, is the first synthetic version of a naturally occurring protein, KLK1. Porcine and human-derived KLK1 have been used for 20+ years in Asia to treat stroke/kidney disease. A near-term Asian strategic partner could provide a $5-$20 million upfront payment with a potential of $50+ million in milestone payments for DM199 distribution rights. Insider buying of 110K+ shares in Q3-2021 is a very positive signal. The average price target from 5 Wall Street analysts is $22, or 5x the current price. A recent capital raise eliminates concern over any future dilution. No capital should be needed until mid-2023 after the pivotal stroke study results are released and the kidney indications.Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 5 | -76 | -67 | N/A | 3 |
| 12/31/2027 | N/A | -57 | -60 | -43 | 5 |
| 12/31/2026 | N/A | -46 | -46 | -40 | 5 |
| 3/31/2026 | N/A | -35 | -31 | -31 | N/A |
| 12/31/2025 | N/A | -33 | -29 | -29 | N/A |
| 9/30/2025 | N/A | -32 | -28 | -28 | N/A |
| 6/30/2025 | N/A | -30 | -26 | -26 | N/A |
| 3/31/2025 | N/A | -27 | -23 | -23 | N/A |
| 12/31/2024 | N/A | -24 | -22 | -22 | N/A |
| 9/30/2024 | N/A | -22 | -19 | -19 | N/A |
| 6/30/2024 | N/A | -20 | -20 | -20 | N/A |
| 3/31/2024 | N/A | -19 | -20 | -20 | N/A |
| 12/31/2023 | N/A | -19 | -19 | -19 | N/A |
| 9/30/2023 | N/A | -18 | -18 | -18 | N/A |
| 6/30/2023 | N/A | -17 | -15 | -15 | N/A |
| 3/31/2023 | N/A | -15 | -13 | -13 | N/A |
| 12/31/2022 | N/A | -14 | -12 | -12 | N/A |
| 9/30/2022 | N/A | -13 | -12 | -12 | N/A |
| 6/30/2022 | N/A | -14 | -12 | -12 | N/A |
| 3/31/2022 | N/A | -13 | -12 | -12 | N/A |
| 12/31/2021 | N/A | -14 | -12 | -12 | N/A |
| 9/30/2021 | N/A | -15 | -13 | -12 | N/A |
| 6/30/2021 | N/A | -14 | -12 | -12 | N/A |
| 3/31/2021 | N/A | -13 | -11 | -11 | N/A |
| 12/31/2020 | N/A | -12 | -9 | -9 | N/A |
| 9/30/2020 | N/A | -11 | -8 | -8 | N/A |
| 6/30/2020 | N/A | -10 | -7 | -7 | N/A |
| 3/31/2020 | N/A | -10 | -9 | -9 | N/A |
| 12/31/2019 | N/A | -11 | N/A | -9 | N/A |
| 9/30/2019 | N/A | -10 | N/A | -9 | N/A |
| 6/30/2019 | 1 | -9 | N/A | -10 | N/A |
| 3/31/2019 | 1 | -8 | N/A | -8 | N/A |
| 12/31/2018 | 1 | -6 | N/A | -6 | N/A |
| 9/30/2018 | 1 | -5 | N/A | -5 | N/A |
| 6/30/2018 | N/A | -4 | N/A | -4 | N/A |
| 3/31/2018 | N/A | -4 | N/A | -4 | N/A |
| 12/31/2017 | N/A | -4 | N/A | -4 | N/A |
| 9/30/2017 | N/A | -4 | N/A | -4 | N/A |
| 6/30/2017 | N/A | -4 | N/A | -4 | N/A |
| 3/31/2017 | N/A | -3 | N/A | -3 | N/A |
| 12/31/2016 | N/A | -2 | N/A | -3 | N/A |
| 9/30/2016 | N/A | -2 | N/A | -2 | N/A |
| 6/30/2016 | N/A | -2 | N/A | -2 | N/A |
| 3/31/2016 | N/A | -1 | N/A | -2 | N/A |
| 12/31/2015 | N/A | -2 | N/A | -2 | N/A |
| 9/30/2015 | N/A | -2 | N/A | -1 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che DMAC rimarrà non redditizia nei prossimi 3 anni.
Guadagni vs Mercato: Si prevede che DMAC rimarrà non redditizia nei prossimi 3 anni.
Guadagni ad alta crescita: Si prevede che DMAC rimarrà non redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che DMAC non avrà alcun fatturato il prossimo anno.
Ricavi ad alta crescita: Si prevede che DMAC non avrà alcun fatturato il prossimo anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di DMAC è previsto essere elevato tra 3 anni
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/18 18:42 |
| Prezzo dell'azione a fine giornata | 2026/05/15 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
DiaMedica Therapeutics Inc. è coperta da 13 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Kyle Bauser | Colliers Securities |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |